Just the facts: Arovella secures $20 million to advance CAR-iNKT Cell Therapy ALA-101

Proactive - Interviews for investors

Proactive's Tylah Tully breaks down ‘Just the Facts’ of the latest news from Arovella Therapeutics Ltd (ASX:ALA). The company has raised $20 million, including a $15 million cornerstone investment, to fully fund its Phase 1 clinical trial for ALA-101, a CAR-iNKT cell therapy targeting CD19-positive blood cancers. The funding will also support the company’s invariant Natural Killer T (iNKT) cell therapy pipeline and solid tumour programs. The capital raise was executed through a placement of 117.6 million shares at $0.17 each, attracting strong support from institutional investors like Pengana Capital Group and a $15 million commitment from an unnamed Australian private investor. Post-raise, Arovella holds $30.6 million in cash and cash equivalents, enabling it to secure IND approval from the US FDA for a Phase 1 trial targeting CD19-positive non-Hodgkin's lymphoma and leukaemia, commence and gather clinical data from the trial, and advance proof-of-concept data for its solid tumour programs focused on gastric and pancreatic cancers. The company emphasised that the raise demonstrates confidence in its CAR-iNKT platform and positions it as a leader in cell therapy innovation. #ProactiveInvestors #ArovellaTherapeutics, #ASX #CARiNKT, #CellTherapy, #CD19, #BloodCancers, #CancerResearch, #Phase1Trial, #ClinicalTrials, #BiotechInvestment, #GastricCancer, #PancreaticCancer, #iNKTCells, #SolidTumours, #BiotechInnovation, #FDAApproval, #CARINKTTherapy, #CancerTreatment, #TherapeuticDevelopment, #InvestorSupport, #ASXBiotech